Timothy Eugene Sullivan Sells 2,892 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 2,892 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total value of $57,232.68. Following the completion of the transaction, the chief financial officer directly owned 104,188 shares of the company’s stock, valued at $2,061,880.52. The trade was a 2.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $85,564.64.

Apellis Pharmaceuticals Stock Up 5.0%

Apellis Pharmaceuticals stock opened at $22.00 on Friday. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $31.17. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 70.97 and a beta of 0.31. The stock’s fifty day moving average is $22.99 and its two-hundred day moving average is $23.49. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business’s revenue for the quarter was up 133.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.46) EPS. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS from Neutral to Buy, citing a stronger-than-expected launch trajectory for the company’s newly approved kidney-disease therapy and assigning a $28 price target — signaling notable upside if commercial momentum continues. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst note argues Apellis’s current valuation understates Empaveli’s (the newly approved rare-kidney-disease drug) revenue potential after early uptake, supporting a re-rating if prescriptions and payor access scale. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (reducing upside expectations) but kept an Overweight stance — a mixed institutional signal that still leaves the company supported by some buy-side analysts. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, which is neutral for near-term flows and may cap upside for investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: A cluster of insider sales on Jan. 20 (including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and other officers) has been disclosed via Form 4 filings — a coordination of sales that can hurt sentiment even if sales are routine diversification. See CEO filing for details. CEO Cedric Francois Form 4

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Marshall Wace LLP increased its stake in Apellis Pharmaceuticals by 11,373.8% in the second quarter. Marshall Wace LLP now owns 2,704,837 shares of the company’s stock valued at $46,821,000 after purchasing an additional 2,681,263 shares during the last quarter. Norges Bank purchased a new stake in Apellis Pharmaceuticals in the 2nd quarter valued at about $40,977,000. AQR Capital Management LLC increased its stake in shares of Apellis Pharmaceuticals by 46.6% during the 2nd quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after acquiring an additional 1,898,995 shares during the last quarter. Polar Capital Holdings Plc increased its stake in shares of Apellis Pharmaceuticals by 96.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock valued at $59,975,000 after acquiring an additional 1,298,055 shares during the last quarter. Finally, Amundi lifted its holdings in shares of Apellis Pharmaceuticals by 386.7% during the 2nd quarter. Amundi now owns 1,604,105 shares of the company’s stock worth $28,585,000 after acquiring an additional 1,274,523 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on APLS. Cantor Fitzgerald cut their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. William Blair reissued an “outperform” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 15th. Wall Street Zen upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reiterated a “sell” rating and set a $19.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Finally, Stifel Nicolaus cut their target price on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.